tradmap

MEDS DataMeds AI, Inc.

$1.70 -4.49%

Data as of close

Industrials · Wholesale-Drugs, Proprietaries & Druggists' Sundries

DataMeds AI, Inc. (MEDS) is an industrial company in the Wholesale-Drugs, Proprietaries & Druggists' Sundries industry, with a market capitalization of $5 million. Shares last traded at $1.70, 86.2% below their 52-week high. Net profit margin is -378.3%, below the peer median of 0.7%. Revenue grew 28.7% year over year.

Market Cap
$5M
Shares Out
3.1M
EPS (TTM)
-$2.61
P/E (TTM)*
—
P/S Ratio
0.22
P/B Ratio
—
Dividend / Share
—
Dividend Yield
—
52-Week High
$12.31
52-Week Low
$0.84
Volume (venue)
6,295
Avg Vol (3m, venue)
103,801.333

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
-14.14%
1M
-50.00%
3M
-45.51%
6M
—
YTD
-77.27%
1Y
—

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
36.83
SMA (50)
$2.50
SMA (200)
$7.14
Price vs SMA50
-32.07%
Price vs SMA200
-76.20%
ATR (14)
$0.52

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$23M
Net Income
-$88M
Gross Margin
-31.2%
Operating Margin
-301.1%
Net Margin
-378.3%
Return on Equity
452.6%
Return on Assets
-269.5%
Current Ratio
0.14
Debt / Equity
-1.63
Revenue Growth (YoY)
+28.7%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 -$7.13 2026-08-17
Q1 2026 -$0.07 2026-05-19
Q4 2025 (derived) $5.05 2026-03-20
FY 2025 -$1.43 2026-03-20
Q3 2025 -$0.46 2025-11-19
Q2 2025 -$5.40 2025-08-19

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Wholesale-Drugs, Proprietaries & Druggists' Sundries peers

MEDS vs 9 industry peers (Wholesale-Drugs, Proprietaries & Druggists' Sundries), by market cap. Data as of close

P/S vs peers
0.22 / 0.26 med
-15% discount
Net margin vs peers
-378.3% / 0.7% med
below median
1–9 of 9
MCKMcKesson Corporation$116.6B25.400.281.1%+0.16%
CORCencora$65.1B24.790.200.8%+0.90%
CAHCardinal Health$58.8B35.400.240.7%-0.55%
HLFHerbalife Ltd.$1.5B8.400.293.4%+8.36%
NUSNU SKIN ENTERPRISES, INC.$228M—0.17-15.7%-1.88%
COSMCosmos Health Inc.$30M—0.41-33.1%-2.07%
ESYNHWH International Inc.$13M———-1.49%
MEDSDataMeds AI, Inc.$5M———-4.49%
HKPDCellyan Biotechnology Co., Ltd$1M———-2.16%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.